|
Breast Carcinoma
|
0.140 |
AlteredExpression
|
disease |
BEFREE |
Recently, researchers discovered that overexpression of FOXK2 inhibits the proliferation and metastasis of breast cancer, non-small cell lung cancer, and colorectal cancer, and is related to the clinical prognosis.
|
29520156 |
2018 |
|
Breast Carcinoma
|
0.140 |
AlteredExpression
|
disease |
BEFREE |
The forkhead transcription factor FOXK2 plays a critical role in suppressing tumorigenesis and mediating cytotoxic drug action in breast cancer.
|
29540677 |
2018 |
|
Breast Carcinoma
|
0.140 |
GeneticVariation
|
disease |
GWASCAT |
Association analysis identifies 65 new breast cancer risk loci.
|
29059683 |
2017 |
|
Breast Carcinoma
|
0.140 |
AlteredExpression
|
disease |
BEFREE |
Significantly, the expression of FOXK2 is progressively lost during breast cancer progression, and low FOXK2 expression is strongly correlated with higher histologic grades, positive lymph nodes, and ERα<sup>-</sup>/PR<sup>-</sup>/HER2<sup>-</sup> status, all indicators of poor prognosis.
|
27773593 |
2016 |
|
Breast Carcinoma
|
0.140 |
AlteredExpression
|
disease |
BEFREE |
FOXK2 transcription factor suppresses ERα-positive breast cancer cell growth through down-regulating the stability of ERα via mechanism involving BRCA1/BARD1.
|
25740706 |
2015 |
|
Body Height
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Waist-Hip Ratio
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Finding of Mean Corpuscular Hemoglobin
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Red blood cell distribution width: Genetic evidence for aging pathways in 116,666 volunteers.
|
28957414 |
2017 |
|
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Red blood cell distribution width: Genetic evidence for aging pathways in 116,666 volunteers.
|
28957414 |
2017 |
|
Reticulocyte count (procedure)
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
Red cell distribution width determination
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
RDW - Red blood cell distribution width result
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
The Allelic Landscape of Human Blood Cell Trait Variation and Links to Common Complex Disease.
|
27863252 |
2016 |
|
NEURODEVELOPMENTAL DISORDER WITH SPASTIC QUADRIPLEGIA AND BRAIN ABNORMALITIES WITH OR WITHOUT SEIZURES
|
0.100 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Forkhead box K2 promotes human colorectal cancer metastasis by upregulating ZEB1 and EGFR.
|
31281520 |
2019 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Particularly, we explore the emerging functions of FOXK2 as a regulator of a broad range of cancer features, such as cell proliferation and survival, DNA damage, metabolism, migration, invasion and metastasis.
|
30897782 |
2019 |
|
Neoplasm Metastasis
|
0.050 |
AlteredExpression
|
phenotype |
BEFREE |
Recently, researchers discovered that overexpression of FOXK2 inhibits the proliferation and metastasis of breast cancer, non-small cell lung cancer, and colorectal cancer, and is related to the clinical prognosis.
|
29520156 |
2018 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Collectively, our results indicate that FOXK2 inhibits the malignant phenotype of ccRCC and acts as a tumor suppressor possibly through the inhibition of EGFR.
|
29368368 |
2018 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Collectively, our results suggest that SUMOylation positively regulates FOXK2 transcriptional activity and has a role in mediating the cytotoxic response to paclitaxel through the tumour suppressor FOXO3.
|
29540677 |
2018 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
FOXK2 inhibits tumor proliferation, migration, and invasion.
|
29520156 |
2018 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
It has been suggested previously that FOXK2 is required to suppress tumor growth; however, the exact role of FOXK2 in gastric cancer remains to be elucidated.
|
30221666 |
2018 |
|
Neoplasm Metastasis
|
0.050 |
Biomarker
|
phenotype |
BEFREE |
Among them, Foxk2 is a ubiquitously expressed family member, but the role of Foxk2 in mediating tumor metastasis in non-small cell lung cancer has not been explored.
|
28260088 |
2017 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Here we showed that FOXK2 expression was increased and associated with tumor size, TNM stage and vascular invasion.
|
28506857 |
2017 |